Genetic Analysis expands into global life science research market through OEM agreement with Merck

Oslo, Norway – 25.11.2026: Genetic Analysis ("GA"), a specialist in microbiome diagnostics has entered into an Original Equipment Manufacturer (OEM) agreement with Merck to supply microbiome profiling products for the global life science research market.

Under the agreement, GA will supply three research-use-only (RUO) microbiome profiling products that Merck will market and distribute under its own name and branding to academic, industrial and commercial research organizations worldwide. The assays will combine the high-plex capability of the Luminex xMAP® technology with GA's unique method for detection and quantification of microbiome targets. The products covered by the agreement are intended solely for research use and are not intended for use in diagnostic procedures or other clinical applications. The products support microbiome characterization and profiling workflows used in fields such as human health research, environmental studies, agricultural sciences, biotechnology, and industrial microbiology.

CEO of GA, Ronny Hermansen, comments:
"*We have spent more than 15 years building our technology and expertise in microbiome profiling, and this agreement represents an important step in broadening how that technology can be commercialized. By working with Merck, we gain a route into the global life science research market while allowing GA to remain focused on what we do best, developing and supplying high-quality microbiome profiling products. For GA, this collaboration expands the applications and customer segments we can address beyond our established diagnostics business and demonstrates the broader commercial potential of our technology platform. We believe this creates a strong foundation for building a scalable research business alongside our diagnostics activities"*

For more information, please contact:
Ronny Hermansen, CEO
E-mail: rh@genetic-analysis.com

About Genetic Analysis
Genetic Analysis AS (GA) is a molecular diagnostics company focused on developing targeted microbiome-based solutions using its proprietary GA-map® platform. With more than 15 years of experience in microbiome research and product development, the company works across disease areas including IBS, IBD, and recurrent *Clostridioides difficile* infection. GA-map® enables standardized and reproducible profiling of clinically relevant microbial patterns, supporting both research and diagnostic applications. GA has a highly qualified team with expertise in molecular biology, bioinformatics, bioengineering, operations, and sales.

For more information: www.genetic-analysis.com www.ga-map.com